A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
Levey AI, Qiu D, Zhao L, Hu WT, Duong DM, Higginbotham L, Dammer EB, Seyfried NT, Wingo TS, Hales CM, Gámez Tansey M, Goldstein DS, Abrol A, Calhoun VD, Goldstein FC, Hajjar I, Fagan AM, Galasko D, Edland SD, Hanfelt J, Lah JJ, Weinshenker D.
Levey AI, et al. Among authors: lah jj.
Brain. 2022 Jun 30;145(6):1924-1938. doi: 10.1093/brain/awab452.
Brain. 2022.
PMID: 34919634
Free PMC article.
Clinical Trial.